mTOR Inhibitor Compound for Neurodegenerative Diseases
Summary
The USPTO granted Patent US12605358B2 to ALIAD BIOPHARMA for a novel mTOR signaling pathway inhibitor compound. The invention was found to inhibit mTORC1 and mTORC2 activities, activate autophagy, and alleviate symptoms associated with Alzheimer's-type dementia in animal models. The patent covers pharmaceutical compositions for preventing or treating nervous system diseases including neurodegenerative diseases and mTORopathy.
What changed
USPTO issued Patent US12605358B2 to ALIAD BIOPHARMA on April 21, 2026, covering a novel compound that inhibits the mTOR signaling pathway. The patent protects compositions for preventing or treating nervous system diseases, including neurodegenerative diseases and mTORopathy, with demonstrated efficacy in Alzheimer's-type dementia animal models. The patent names Yunhee Kim, Hyockman Kwon, and Young Taek Han as inventors and claims the compound's ability to inhibit mTORC1 and mTORC2 activities and activate autophagy.
For pharmaceutical companies and drug manufacturers developing neurodegenerative disease therapies, this patent represents an intellectual property barrier in the mTOR inhibitor space. Companies pursuing similar mTORC1/mTORC2 targeting approaches for nervous system indications should conduct freedom-to-operate analyses to assess potential overlap with the claims of US12605358B2.
Archived snapshot
Apr 21, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Composition for preventing or treating nervous system diseases comprising compound that inhibits mTOR signaling pathway as active ingredient
Grant US12605358B2 Kind: B2 Apr 21, 2026
Assignee
ALIAD BIOPHARMA
Inventors
Yunhee Kim, Hyockman Kwon, Young Taek Han
Abstract
The present invention relates to a novel compound that inhibits the mTOR signaling pathway, a method for preparing same, and a pharmaceutical composition comprising same as an active ingredient. The compound of the present invention was found to inhibit mTORC1 and mTORC2 activities, activate autophagy, and alleviate a series of disease symptoms associated with Alzheimer's-type dementia in dementia model animals, and thus can be effectively used as a pharmaceutical composition capable of preventing or treating nervous system diseases comprising neurodegenerative diseases and mTORopathy.
CPC Classifications
A61K 31/357 A61P 25/28
Filing Date
2022-02-16
Application No.
18277701
Claims
9
Parties
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.